AN AUTORADIOGRAPHIC ANALYSIS OF [3H]α-BUNGAROTOXIN DISTRIBUTION IN THE RAT BRAIN AFTER INTRAVENTRICULAR INJECTION

J. SILVER and R. B. BILLIAR. From the Department of Reproductive Biology, University Hospitals, Case Western Reserve University, Cleveland, Ohio 44106. Dr. Silver's present address is the Department of Neuroscience, The Children's Hospital Medical Center, Harvard University, Boston, Massachusetts 02115

Alpha-bungarotoxin (α-BuTX) had been found to block neuromuscular transmission by an antidepolarizing action (6). It has been suggested that α-BuTX binds irreversibly and with high specificity to the nicotinic-acetylcholine receptor of the postsynaptic membrane (6, 17), and that d-tubocurarine protects these receptors from the toxin (7, 19).

These conclusions have been substantiated by the autoradiographic findings that, in mice, 131I-labeled α-BuTX accumulates within the motor end-plate region of various muscles (11, 17) in the same manner as radioactive curare (27). Here, we report the presence, in vivo, utilizing light microscope autoradiography, of a similar type of α-
BuTX binding in the hypothalamus and amygdala of the rat brain.

MATERIALS AND METHODS

α-Bungarotoxin was isolated from the lyophilized venom of Bungarus multicinctus (Miami Serpentarium Laboratories, Miami, Fla., and Sigma Chemical Company, St. Louis, Mo.) by a modification of the method of Lee et al. (18). The venom was first chromatographed on washed CM-Sephadex C-50, and fraction II (18) was isolated and further purified by CM-cellulose chromatography (18). Although Lee et al. (18) used 0.05 M NH₄OAc, pH 5.0, to elute two protein fractions, this buffer did not elute our fraction II from the CM-cellulose and the buffer concentration was increased to 0.1 M NH₄OAc, pH 6.0, which then resolved fraction II into two protein fractions. The second fraction (II-B) contained about 70% of the protein applied to the column and was lyophilized and desalted on Sephadex G-25 column equilibrated with 0.05 M NaH₂PO₄, pH 7.5. 5 μg/ml of fraction II-B reduced in vitro isometric contraction of the rat diaphragm (30-s interval stimulation of the phrenic nerve) to half-strength in 18-19 min and completely blocked contraction in about 30 min. These results indicate that fraction II-B had the properties of α-BuTX (6). Protein concentration was determined by optical density at 260 and 280 nm. Fraction II-B (25, 50, and 100 μg) was analyzed by disc electrophoresis (15% cross linking; stacked at pH 5.0, and run at pH 4.3, [alanine-acetate buffer]) and only one protein staining band was observed.

[3H]α-Bungarotoxin ([3H]α-BuTX) was prepared by the acetamidination method of Zull and Repke (30) for the preparation of tritiated polypeptides. The [3H]acetamidino-α-bungarotoxin ([3H]α-BuTX) (sp act ~1.5 μCi/μg) was separated from unreacted [methyl-3H]acetimidate hydrochloride by gel filtration on Sephadex G-25. The [3H]α-BuTX appeared radiochemically pure as indicated by disc electrophoresis (Fig. 1), and the [3H]α-BuTX had the same electrophoretic mobility as the α-BuTX before acetamidination. In the rat phrenic nerve-diaphragm preparation, the [3H]α-BuTX inhibited indirect-stimulated muscle contraction in the same time as the radioinert α-BuTX. Both [3H]α-BuTX and α-BuTX were stored at -15°C in 0.05 M NaH₂PO₄ buffer, pH 7.5.

Since α-BuTX does not readily pass the blood-brain barrier (17) and since our studies are primarily directed toward the hypothalamus, the [3H]α-BuTX was injected intracranially. Female Holtzman rats (250-300 g) were placed in a stereotaxic instrument under ether anesthesia. With the use of bregma coordinates of Pellegrino and Cushman (21), 0.8 mm anterior, 7.5-8.0 mm ventral, and 0.0 mm lateral, a fine glass cannula was inserted into the third ventricle of the diencephalon in a region of the preoptic nuclei, and one of the following solutions was infused: (a) 7.0 μg of [3H]α-BuTX (8.75 × 10⁻⁴ M) in 10.0 μl of (0.05 M; pH 7.4) NaH₂PO₄ buffer; (b) to test for possible nicotinic specificity of toxin binding, 7.0 μg of d-tubocurarine chloride (1.0 × 10⁻⁳ M) in 10.0 μl of buffer followed 30 min later by the same solution as in (a); (c) to test for possible muscarinic specificity of toxin binding, 3.5 μg of atropine sulfate (1.0 × 10⁻³ M atropine) in 10.0 μl of buffer followed 30 min later by the same solution as in (a); (d) to test for nonspecific binding, uptake, or retrograde transport within cells, 1.6 μg of [3H]parathyroid hormone ([3H]PTH) (31) (2.0 × 10⁻⁸ M; 1.0 μCi/μg) in 20.0 μl of (50.0 mM; pH 7.0) HOAC buffer; (e) to test for positive chemography (8), the same concentration as in (a) of radioinert α-BuTX (but no [3H]α-BuTX) in 10.0 μl of sodium phosphate buffer. The cannula remained in place throughout the combined infusions in series (b) and (c). The various solutions were infused manually at an approximate rate of 1.0 μl/min. The injections of α-BuTX did not cause any overt symptoms.

The animals were anesthetized with ether and sacrificed 2, 12, or 24 h after injection by perfusion through the heart with, first, 10-20 ml of 0.9% saline and then 400 ml of 10% Formalin-0.9% saline fixative, both 37°C. The brains were placed in saline-Formalin solution for 1 wk and then processed routinely for paraffin embedding. Coronal sections were cut at 13 μm, mounted on glass slides, deparaffinized, and coated with Kodak NTB-2 nuclear tract, autoradiographic emulsion. The coated slides were stored in a light-proof container at 4°C for 4 wk, and then processed photographically, cover slipped, and examined under the phase contrast microscope.

RESULTS

[3H]α-BuTX

2 h after stereotaxic infusion of [3H]α-BuTX into the third ventricle (two animals), label was dispersed throughout the entire brain. Grain density was highest over brain tissue immediately surrounding the third ventricle and especially around the endothelium of blood vessels. Proceeding radially from the ventricle along its entire length, levels of grain density were progressively diminished. High concentrations of label were found overlying the upper portion of the ependymal zone which lines the third ventricle. In addition, a few isolated loci of dense label accumulation were scattered over the arcuate region of the hypothalamus.

12 h (two animals) and 24 h (three animals) after injection of [3H]α-BuTX, the intensity of label overlying the greater part of the brain and around vascular endothelium was greatly decreased. No striking difference in labeling pattern was observed between the 12-h and 24-h animals. In several discrete areas the density of labeling was...
markedly increased (Figs. 2-4). The most outstanding of these zones appeared as a series of contiguous clusters of intense radioactive label extending throughout the mediobasal region of the hypothalamus and the central nucleus of the amygdala. Thus, proceeding mediolaterally, accumulations of label were seen overlying (a) the ependymal zone on either side of the third ventricle, directly opposite and slightly dorsal to the medial boundary of the arcuate nucleus (Fig. 2), (b) the arcuate nucleus (Fig. 2), (c) the base of the tuber cinereum (Fig. 2), (d) the ventralmost aspect of the lateral hypothalamic area but immediately dorsal to the optic tract, (e) the supraoptic nucleus (Fig. 5), and (f) the central amygdaloid nucleus. In one animal at 24 h label was also present over the medial nuclei of the amygdala and habenula.

More rostrally, below the third ventricle, label appeared in the midline and was continuous with that spreading bilaterally along the base of the brain towards the supraoptic nuclei. Further forward, but continuous with more caudal labeled regions, the preoptic suprachiasmatic (Fig. 3) and suprachiasmatic nuclei (Fig. 4) were heavily labeled. These dense labeling patterns were bilateral in all instances. In addition, throughout the uppermost wall and roof of the third ventricle, silver grains were concentrated over the internal glial cell layer of the ependymal region.

**d-Tubocurarine Pretreatment Followed by [3H]α-BuTX**

2 h (one animal), 12 h (two animals), and 24 h (one animal) after the combined administration of first tubocurarine and then [3H]α-BuTX, the pattern of diffuse labeling overlying the brain was similar to that after the injection of [3H]α-BuTX alone (compare Fig. 6a and b). However, intense label accumulations over the central amygdaloid nucleus, basolateral hypothalamus, arcuate region, and supraoptic and suprachiasmatic nuclei were lacking. Label was still present at the upper ependymal zone of the third ventricle, but was diminished over the lower ependymal rostral and adjacent to the arcuate nucleus (compare Fig. 6a-c).

**Atropine Pretreatment Followed by [3H]α-BuTX**

12 h (two animals) after the combined injection of first atropine and then [3H]α-BuTX, the pattern of labeling over the brain was comparable to that seen 12 h after injection with [3H]α-BuTX alone (Fig. 6a).

**[3H]PTH**

2, 12, and 24 h (one animal per time period) after the injection of [3H]PTH, the general distribution of diffuse label over the brain was similar to that seen after injection of [3H]α-BuTX (Fig. 6c). At each time, PTH label was also present over the ependymal and adjacent glial layer of the roof and upper section of the third ventricle and around blood vessels. However, the heavily labeled areas of the lower ependymal region of the third ventric-
FIGURE 5 Light micrograph of the supraoptic nucleus (24 h) showing BuTX labeling (arrows). OT, optic tract. (× 400).

...cle, mediobasal, and basolateral hypothalamus, and central amygdaloid nucleus were absent.

\[ \text{NaH}_2\text{PO}_4 \text{ Buffer} + \alpha\text{-BuTX (Radioinert)} \]

12 and 24 h (one animal per time period) after the injection of radioinert \( \alpha\text{-BuTX} \) in buffer solution, the grain densities overlying the entire brain were at background levels.

DISCUSSION

Taken together, the various patterns of labeling with \[^{3}\text{H}\] \( \alpha\text{-BuTX} \) alone and with competitors suggest the presence of a discrete and pharmacologically specific population of nicotinic-cholinergic neurons within the mediobasal and basolateral portions of the hypothalamus, and the central nucleus of the amygdala. Whether labeling in these regions is indicative of a pathway coursing horizontally between the arcuate region and the amygdala is unknown. However, a bundle of such course has been demonstrated by the use of various classical anatomical techniques (25). Although the chemical nature of the \(^{3}\text{H}\) or the concentrating mechanism in the hypothalamus is not presently known, \( \alpha\text{-BuTX} \) is believed to bind specifically and essentially irreversibly to the cholinergic receptor at the end-plate region of the diaphragm muscle. Radioactive bungarotoxin, however, has also been demonstrated to be associated with non-end-plate elements of the diaphragm in vitro (23), but this appears to be related to the concentration of \( \alpha\text{-BuTX} \) present in the incubation medium. After in vivo injection, however, most of the neurotoxin was associated with the end-plate region (23). In the present studies \[^{3}\text{H}\]PTH, a polypeptide with a molecular weight and a basic and acidic amino acid composition similar to that of \[^{3}\text{H}\] \( \alpha\text{-BuTX} \), did not result in intense labeling as observed with \[^{3}\text{H}\] \( \alpha\text{-BuTX} \). Also, tubocurarine, but not atropine, reduced \[^{3}\text{H}\] \( \alpha\text{-BuTX} \) accumulation within the mediobasal hypothalamus and central amygdaloid nucleus, whereas neither drug had an appreciable effect on toxin labeling elsewhere in the brain. These data suggest the possibility that \( \alpha\text{-BuTX} \) labeling over hypothalamic and amygdalar tissue may represent binding with high specificity to cholinergic membrane receptors, rather than nonspecific or possible axonal membrane (10) binding or general uptake within neurons. The retention of the labeling pattern for 24 h supports this suggestion. Other areas of dense label accumulation, such as the ependymal roof of the third ventricle and the endothelium of blood vessels, may represent sites of nonspecific toxin accumulation related to cerebrospinal fluid or blood-brain barriers (Fig. 6a-c) (4, 14).

Although in vivo and in vitro analyses of brain preparations with the use of \( \alpha\text{-neurotoxins} \) and various other techniques have suggested the existence of cholinergic neuronal elements within and also distant from the hypothalamus and amygdala (1, 9, 10, 15, 16, 22, 24, 28), in the present study the limited diffusion of \[^{3}\text{H}\] \( \alpha\text{-BuTX} \) from the third ventricle may prevent (or delay in animals at 2 h post-injection) autoradiographic labeling of peripherally located areas. Furthermore, recent studies on nerve-muscle systems have shown that the association, as well as the dissociation, reactions between \( \alpha\text{-bungarotoxin} \) and “high affinity” ACh receptor sites may occur slowly (over many minutes or hours) (5, 12). If present centrally, comparably slow binding phenomena could also influence the temporal pattern of \( \alpha\text{-BuTX} \) labeling. Other sites and methods of toxin injection
FIGURE 6 (a) Dark-field photomicrograph of the arcuate region of the hypothalamus in an animal which was injected with atropine and then 30 min later with [3H]-a-BuTX and sacrificed after 12 h. Note: (i) the persistence of heavy labeling over the arcuate region (A) and the adjacent portion of the lower ependymal wall, and (ii) the heavy labeling over the upper wall of the third ventricle (arrow). V, ventricle. (x 100). (b) Dark-field photomicrograph of the arcuate region of the hypothalamus in an animal which was injected with tubocurarine and then 30 min later with [3H]-a-BuTX and sacrificed after 12 h. Note: (i) the absence of heavy labeling over the arcuate region and nearby ependyma; and (ii) the presence of labeling over the upper ependymal zone (arrow). V, ventricle. (x 100). (c) Dark-field photomicrograph of the arcuate region of the hypothalamus in an animal which was injected with [3H]-PTH alone and then sacrificed after 12 h. Note: (i) the absence of intense labeling over the arcuate region; and (ii) the accumulation of label over the roof of the third ventricle (arrow). Labeling of blood vessel endothelium is readily apparent in this section (e.g., above asterisk). V, ventricle. (x 100).

may serve to elaborate additional cholinergic centers. In this regard Polz-Tejera et al. (22) have recently studied the in vitro binding of [125I]a-BuTX in the central nervous system of the rat by light microscope autoradiography and reported heavy labeling in the supraoptic nucleus and also the hippocampus. In that note (22), the presence or absence of labeling in other areas of the hypothalamus was not discussed.

A large portion of the a-BuTX label in the hypothalamus may overlap an anatomically and functionally well-defined neurosecretory region within the so-called "hypophyseotropic area" of the diencephalon (13). This region, anatomically defined as a portion of the mediobasal hypothalamus immediately caudal to the preoptic area and rostral to the mamilary bodies, can maintain a pulsatile rhythm of high circulating concentrations...
of luteinizing hormone even when deprived of its total afferent input (2, 13). It is premature to
tell whether synapses involved in the release of
neurohormones have been labeled by \[\text{^3}H\]a-BuTX.

The \(\alpha\)-BuTX labeling over the lower portion
of the third ventricle may be of nerve cell processes
rather than of ependymal cells. The differential
effect of \(d\)-tubocurarine (but not atropine) pre-
treatment on the pattern of labeling over the up-
per and lower walls of the third ventricle, and the
contrast of labeling between these two zones in
\([\text{^3}H]\)PTH-injected animals, support this hypothe-
sis (Fig. 6a-c). The position of labeling at the
lower portion coincides with a region of contact
between the third ventricle and a system of infun-
dibular - cerebrospinal fluid - contacting (I- CSF)
neurons (26). It has been suggested that, via the I-
CSF neurons, luteinizing hormone-releasing hor-
mones may be released directly into the third ventricle and thereby transported
within the CSF to the median eminence, where
substances may be resorbed by tanycyte processes
(3, 20, 26, 29). It is noteworthy that the median
eminence, the primary site of the ependymal tan-
cytes, remained largely free of \(\alpha\)-BuTX label.

SUMMARY

Purified \(\alpha\)-bungarotoxin was isolated by chroma-
tography and made radioactive with tritium
\([\text{^3}H]\)acetamidino-\(\alpha\)-bungarotoxin). Infusions of
\([\text{^3}H]\)a-bungarotoxin alone or preceded by tubocu-
arine or atropine were given into the third ventri-
cle. 2, 12 or 24 h after injection the brains were
prepared for autoradiography. Injections of \(\alpha\-
bungarotoxin \) (radioinert) in buffer, or of
\([\text{^3}H]\)parathyroid hormone in buffer, served as con-
trasts. The various patterns of labeling suggest the
presence of nicotinic-cholinergic neurons within
the arcuate and basolateral regions of the hypo-
thalamus including the supraoptic and suprachias-
matic nuclei and, in addition, the central nucleus of
the amygdala.

The authors wish to extend sincere appreciation to Dr.
W. A. Johnson for assistance during the stereotaxic
surgery and to Drs. S. Kuo and N. Robbins of the
Anatomy Department at Case Western Reserve Univer-
sity for testing the physiological activity of our toxin. The
[methyl-\(\text{^3}H\)]acetamidate and \([\text{^3}H]\)PTH were generously
provided by Drs. C. Malbon and J. Zull, Department of
Biology, CWRU.

J. Silver was supported by National Institutes of
Health Training Grant HD-00024 and Ford Founda-
ing Training Grant 670-0135A. R. B. Billiar was a recipient
of Career Development Award, National Institute of
Child Health and Human Development Grant HD-
42564. This research was supported in part by U. S.
Public Health Service HD-02378 and Program Project
HD-07640.

Received for publication 19 February 1976, and in re-
vised form 29 July 1976.

Note Added in Proof: Recently, Gnodde and Schuiling
(\textit{Neuroendocrinology, 1976.} \textit{20:} 212-223) have shown
that mecamylamine, a cholinergic nicotinic receptor
blocking agent, when injected intraperitoneally, de-
creased plasma LH levels in ovariectomized rats,
whereas scopolamine, a cholinergic muscarinic receptor
blocking agent, had no effect on plasma LH levels.

REFERENCES

1. \textit{Beld, A. J., S. Van Den Hoven, A. C. Wou-
terse, and A. P. Zeegers.} \textit{1975.} Are muscarinic
receptors in the central and peripheral nervous sys-
tem different? \textit{Eur. J. Pharmacol.} \textit{30:} 360-363.
2. \textit{Blake, C. A., and C. H. Sawyer.} \textit{1974.} Effects of
hypothalamic deafferentation on the pulsatile
rhythm in plasma concentrations of luteinizing hor-
mones in ovariectomized rats. \textit{Endocrinology.}
\textit{94:730-736.}
3. \textit{Brawer, J. R.} \textit{1972.} The fine structure of the
ependymal tanyctes at the level of the arcuate
nucleus. \textit{J. Comp. Neurol.} \textit{145:} 25-42.
4. \textit{Brightman, M. W.} \textit{1965.} The distribution within
the brain of ferritin injected into cerebrospinal fluid
compartments. \textit{J. Cell Biol.} \textit{26:} 99-123.
5. \textit{Brookes, J. P., and Z. W. Hall.} \textit{1975.} Acetylchlo-
rine receptors in normal and denervated rat dia-
phragm muscle. I. Purification and interaction with
\([\text{^3}H]\)-\(\alpha\)-bungarotoxin. \textit{Biochemistry.}
\textit{14:} 2092-2099.
6. \textit{Chang, C. C., and C. Y. Lee.} \textit{1963.} Isolation of
neurotoxins from the venom of \textit{Bungarus multicinc-
tus} and their modes of neuromuscular blocking ac-
tion. \textit{Arch. Int. Pharmacodyn. Ther.} \textit{144:} 241-257.
7. \textit{Changeux, J. P., M. Kasai, and C. Y. Lee.} \textit{1970.}
Use of a snake venom toxin to characterize the
cholinergic receptor protein. \textit{Proc. Natl. Acad. Sci.
U. S. A.} \textit{67:} 1241-1247.
8. \textit{Daniels, J. S., and S. A. Gilmore.} \textit{1975.} Chem-
ography associated with specific anatomic areas in
autoradiographs of brain stems from adult rats.
\textit{Brain Res.} \textit{98:} 343-347.
9. \textit{Dyball, R. E. J., R. G. Dyer, and R. F. Drew-
ett.} \textit{1974.} Chemical sensitivity of preoptic neurons
which project to the medial basal hypothalamus.
\textit{Brain Res.} \textit{71:} 140-143.
10. ETEROVIC, V. A., and E. L. BENNETT. 1974. Nicotinic cholinergic receptor in brain detected by binding of $\alpha$-bungarotoxin. Biochim. Biophys. Acta. 362:346-355.

11. FERTUCK, H. C., and M. M. SALPETER. 1974. Localization of acetylcholine receptor by $^{3}H$-labeled $\alpha$-bungarotoxin binding at mouse motor end plates. Proc. Natl. Acad. Sci. U. S. A. 71:1376-1378.

12. FERTUCK, H. C., W. WOODWARD, and M. M. SALPETER. 1975. In vivo recovery of muscle contraction after $\alpha$-bungarotoxin binding. J. Cell Biol. 66:209-213.

13. HALASZ, B. 1969. In Frontiers in neuroendocrinology. W. F. Ganong, and L. Martini editors. Oxford University Press, New York.

14. HAYMAKER, W. 1969. In The Hypothalamus. W. Haymaker, E. Anderson, and W. J. H. Nauta, editors. Charles C Thomas Publisher, Springfield, Ill. 219-250.

15. JACOBOWITZ, D. M., and M. PALKOVITS. 1974. Topographic atlas of catecholamine and acetylcholinesterase-containing neurons in the rat brain. I. Forebrain (telencephalon, diencephalon). J. Comp. Neurol. 157:13-28.

16. KRNAMEVI, K. 1969. Central cholinergic pathways. Fed. Proc. 28:113-119.

17. LEE, C. Y., and L. F. TSENG. 1966. Distribution of Bungarus multicinctus venom following envenomation. Toxicon. 3:281-290.

18. LEE, C. Y., S. L. CHANG, S. T. KAU, and S. H. LUIH. 1972. Chromatographic separation of the venom of Bungarus multicinctus and characterization of its components. J. Chromatogr. 72:71-82.

19. MILLED, R., and L. T. POTTER. 1971. Acetylcholine receptors in muscle fibrils. Nature (Lond.). 233:599-603.

20. ONGO, J. G., R. L. ESKEY, R. S. MCAL, and J. C. PORTER. 1973. Release of LH by LRF injected into the CSF: A transport role for the median eminence. Endocrinology. 93:231-237.

21. PELLEGRENO, L. J., and A. J. CUSHMAN. 1967. A stereotaxic atlas of the rat brain. Appleton-Century-Crofts. New York.

22. POLZ-TJEJERA, G., J. SCHMIDT, and H. J. KARTEN. 1975. Autoradiographic localisation of $\alpha$-bungarotoxin-binding sites in the central nervous system. Nature (Lond.). 258:349-351.

23. PORTER, C. W., T. H. CHIU, T. WIECKOWSKI, and E. A. BARNARD. 1973. Types and locations of cholinergic receptor-like molecules in muscle fibers. Nature (Lond.). 241:3-7.

24. SALVATERRA, P. M., H. R. MAHLER, and W. J. MOORE. 1975. Subcellular and regional distribution of $^{125}$I-labeled $\alpha$-bungarotoxin binding in rat brain and its relationship to acetylcholinesterase and choline acetyltransferase. J. Biol. Chem. 250:6469-6475.

25. SZEHTAGOTHAI, J., B. FLERKO, B. MESS, and B. HALASZ. 1968. Hypothalamic control of the anterior pituitary. Akademiai Kaido. Budapest. 22-109.

26. WASSER, P. G., and U. LUTHI. 1957. Autoradiographische lokalisation von $^{14}$C-calebassen-curarin I und $^{14}$C-decamethonium in der motorischen endplatte. Arch. Inter. Pharmacodyn. Ther. 112:272-296.

27. YAMAMURA, H. I., M. J. KUHAR, and S. H. NYDER. 1974. In vivo identification of muscarinic cholinergic receptor binding in rat brain. Brain Res. 80:170-176.

28. ZIMMERMAN, E. A., K. C. HSU, M. FERIN, and G. P. KOZLOWSKI. 1974. Localization of gonadotropin-releasing hormone (Gn-RH) in the hypothalamus of the mouse by immunoperoxidase technique. Endocrinology. 95:1-8.

29. ZULL, J. E., and D. W. REPKE. 1972. Studies with tritiated polypeptide hormones. I. The preparation and properties of an active, highly tritiated derivative of parathyroid hormone: acetamidinoparathyroid hormone: J. Biol. Chem. 247:2183-2188.

30. ZULL, J. E., and J. CHUANG. 1975. Further studies on acetamidination as a technique for preparation of a biologically valid $^3$H-labeled tracer for parathyroid hormone. J. Biol. Chem. 250:1668-1675.